Core Viewpoint - Novartis has successfully completed the acquisition of Regulus Therapeutics Inc., enhancing its pipeline for treating autosomal dominant polycystic kidney disease (ADPKD) [1][2][3] Group 1: Acquisition Details - The acquisition was finalized with Regulus becoming an indirect wholly owned subsidiary of Novartis, and its shares have ceased trading on the Nasdaq [1] - Novartis offered $7.00 in cash per share plus a contingent value right (CVR) for each share, with approximately 56.37 million shares validly tendered, representing about 74.49% of the outstanding shares [3][4] - The merger was executed without a vote from Regulus' stockholders, resulting in the cancellation of shares not tendered in the offer [4] Group 2: Clinical Development - The acquisition aims to advance the clinical development of farabursen, an investigational oligonucleotide targeting miR-17, which shows promise in treating ADPKD by reducing cyst growth and delaying disease progression [2] - The Phase 1b clinical trial for farabursen demonstrated promising efficacy and safety, impacting urinary polycystin levels and total kidney volume, which are critical measures of disease progression [2]